Assess efficacy and safety of Durvalumab alone or combined with Bevacizumab in high risk of recurrence HCC patients after curative treatment - EMERALD-2

Exclusion Criteria

• - Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
• - Evidence of metastasis, macrovascular invasion or co-existing malignant disease on baseline imaging
• - History of hepatic encephalopathy within 12 months prior to randomization
• - Evidence, by Investigator assessment, of varices at risk of bleeding on upper endoscopy or contrast-enhanced cross-sectional imaging
• - Patients with Vp1 to Vp4 portal vein thrombosis on baseline imaging are excluded
• - Active co-infection with HBV and HDV.
• - Receipt of prior systemic anticancer therapy for HCC
• - Those on a waiting list for liver transplantation